United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Pharma Industry News Praxis Precision Medicines faces major setback in ulixacaltamide trial but remains committed to Essential3 study Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, encountered… byPallavi MadhirajuFebruary 28, 2025